April 20, 2024
Market Now
Kolon Life Science inks W16.9b gene therapy deal
[DISCLOSURE] Kolon Life Science (102940) announced on June 20 that it has signed a 16.9 billion won (US$15.27 million) contract with Zhongji 1 International Medical Group (Hong Kong) to supply Invossa-K in Hong Kong, Macau and Mongolia.
This amounts to 14.3 percent of its 2017 revenue and the contract is valid for 5 years.
By Hwang You-mee (glamazon@heraldcorp.com)
This amounts to 14.3 percent of its 2017 revenue and the contract is valid for 5 years.
By Hwang You-mee (glamazon@heraldcorp.com)
